Table 9.

Summary of the aim of the study and of the quantitative findings.

[Combination therapy of onabotulinumtoxinA + anti-CGRP mAbs] compared with [baseline] for [chronic migraine]
Patient or population: [patients] with [chronic migraine] Settings: [real-world] Intervention: [Combination therapy of onabotulinumtoxinA + anti-CGRP mAbs] Comparison: [OnabotulinumtoxinA alone]
Outcomes	Effect (95% CI)	Quality of the evidence (GRADE)
Change in mean ± SD of MHDs after 3 months of combination treatment	MD −2.67, 95% CI −4.42 to −0.93; participants = 393 intervention and 496 baseline; studies = 5; I2 = 49%	⊕⊕⊕⊝ moderate
CI: Confidence interval; MD: Mean difference.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.